Platelet Aggregation Inhibitors
"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
| Descriptor ID |
D010975
|
| MeSH Number(s) |
D27.505.954.502.780
|
| Concept/Terms |
Platelet Aggregation Inhibitors- Platelet Aggregation Inhibitors
- Aggregation Inhibitors, Platelet
- Inhibitors, Platelet Aggregation
- Blood Platelet Antiaggregants
- Antiaggregants, Blood Platelet
- Platelet Antiaggregants
- Antiaggregants, Platelet
- Blood Platelet Aggregation Inhibitors
Antiplatelet Agents- Antiplatelet Agents
- Agents, Antiplatelet
- Antiplatelet Drugs
- Drugs, Antiplatelet
Platelet Antagonists- Platelet Antagonists
- Antagonists, Platelet
- Blood Platelet Antagonists
- Antagonists, Blood Platelet
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".
This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 2000 | 1 | 2 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 4 | 3 | 7 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 3 | 5 | 8 |
| 2011 | 2 | 2 | 4 |
| 2012 | 4 | 1 | 5 |
| 2013 | 1 | 2 | 3 |
| 2014 | 6 | 5 | 11 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 3 | 6 |
| 2019 | 2 | 2 | 4 |
| 2020 | 3 | 1 | 4 |
| 2021 | 11 | 3 | 14 |
| 2022 | 4 | 6 | 10 |
| 2023 | 3 | 10 | 13 |
| 2024 | 5 | 9 | 14 |
| 2025 | 11 | 2 | 13 |
| 2026 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.
-
Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source: Secondary Analysis of the CASPR Registry. Neurol Clin Pract. 2026 Aug; 16(4):e200631.
-
Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association. Stroke. 2026 Aug; 57(8):e437-e454.
-
Multicenter evaluation of the safety and efficacy of varying doses of cangrelor used in acute cerebrovascular stenting in patients with acute ischemic stroke. J Neurointerv Surg. 2026 Apr 16; 18(5):1372-1377.
-
Recurrent Stroke in Patients With Cryptogenic Stroke and Left Ventricular Injury: The Cardiac Abnormalities in Stroke Prevention and Recurrence (CASPR) Study. Stroke. 2026 May; 57(5):1175-1186.
-
Aspirin-ticagrelor use after mild acute ischemic stroke: Findings from the get with the guidelines-stroke registry. J Stroke Cerebrovasc Dis. 2026 Mar; 35(3):108564.
-
Shortened dual antiplatelet therapy duration after percutaneous patent foramen ovale and atrial septal defect closure. J Invasive Cardiol. 2025 Dec; 37(12).
-
Comparative effectiveness of reduced dose Ticagrelor, full dose Ticagrelor, and Clopidogrel in acute stroke management. J Clin Neurosci. 2026 Jan; 143:111752.
-
Impact of duration of dual anti-platelet therapy on risk of complications after stent-assisted coiling of unruptured aneurysms. J Neurointerv Surg. 2025 Aug 13; 17(9):956-960.
-
Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trial. Contemp Clin Trials. 2025 09; 156:108030.
-
Outcomes for single antiplatelet, dual antiplatelet, or oral anticoagulation after Amulet: Insights from EMERGE LAA post-approval study. Cardiovasc Revasc Med. 2026 05; 86:1-9.